US$ 23.34
glp-1 small molecule agonist A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency GLP-1 Receptor Agonists as Treatments
Description
The most common side effects for all agents in this drug class are nasopharyngitis, headache, and upper respiratory tract infection

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis

doi: 10.1016/j.ejphar.2018.08.020 157 PerlmanG.SimmonsA
Zea-Vera A, Cordova EG, Rodriguez S, et al

Use of antihyperglycemic drugs and risk of cancer in patients with diabetes

Nonetheless, mice deficient for GRP have impaired glucose tolerance, reduced first-phase insulin secretion and impaired GLP-1 secretion in response to an oral glucose challenge [343]